Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P13 Extension Study in Rheumatoid Arthritis
NCT01571219Phase 3Completed
- Sponsor
- Celltrion
- Start
- Mar 2012
- Primary completion
- Jul 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of infliximab-dyyb in rheumatoid arthritis (RA), sponsored by Celltrion. Primary endpoints: American College of Rheumatology criteria at 40 weeks, Immunogenicity at 40 weeks and 1 more. Started Mar 2012; status: completed.
02
Drugs
infliximab-dyyb
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01571219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01571219.